Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years

This study has been completed.

Study NCT00161954 Information provided by Baxter Healthcare Corporation

First Received: September 8, 2005 Last Updated: October 19, 2006 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	May 2004
Estimated Primary Completion Date:	No date given

No publications provided by Baxter Healthcare Corporation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Orlinger KK, Hofmeister Y, Fritz R, Holzer GW, Falkner FG, Unger B, Loew-Baselli A, Poellabauer EM, Ehrlich HJ, Barrett PN, Kreil TR. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis. 2011 Jun 1;203(11):1556-64.